Literature DB >> 33522920

What is the most cost-effective strategy for nasal screening and Staphylococcus aureus decolonization in patients undergoing total hip arthroplasty?

Hisahiro Tonotsuka1,2, Hajime Sugiyama3,4, Ayano Amagami3,4, Keigo Yonemoto3,4, Ryuichi Sato3,4, Mitsuru Saito4.   

Abstract

BACKGROUND: To reduce periprosthetic joint infection after total hip arthroplasty (THA), several nasal screening and decolonization strategies for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) have been performed. These include universal decolonization (UD; i.e., no screening and decolonization for all patients), universal screening and target decolonization (US; i.e., screening for all patients and decolonization for bacterial positive patients), and target screening and decolonization (TS; i.e., screening and decolonization for high-risk populations only). Although TS is the most cost-effective strategy, useful risk factors must be identified. The purpose of this study was to evaluate the presence of predictive factors that enable the TS strategy to be successfully implemented and to compare the costs of each strategy.
METHODS: A total of 1654 patients scheduled for primary or revision THA (1464 female, 190 male; mean age 64 years) were screened prior to surgery for bacterial colonization of the nasal mucosa. Risk factors for positive MRSA and S. aureus (including both MRSA and MSSA) tests were analyzed according to the following parameters: sex, age ≥ 80 years, body mass index ≥ 30 kg/m2, antibiotic use within 3 years, corticosteroid use, serum albumin < 3.5 g/dL, glomerular filtration rate < 50 mL/min, presence of brain, thyroid, cardiac, or pulmonary disease, diabetes, asthma, smoking status, and whether revision surgery was performed. The average cost of each strategy was calculated.
RESULTS: In total, 29 patients (1.8 %) tested positive for MRSA and 445 (26.9 %) tested positive for S. aureus. No parameters were identified as independent risk factors for MRSA and only female sex was identified as a risk factor for S. aureus (p = 0.003; odds ratio: 1.790; 95 % confidence interval: 1.210-2.640). The average cost of each strategy was 1928.3 yen for UD, 717.6 yen for US, and 717.6 yen for TS (for eradicating MRSA), and 1928.3 yen for UD, 1201.6 yen for US, and 1160.4 yen for TS (for eradicating S. aureus).
CONCLUSIONS: No useful predictive parameters for implementing the TS strategy were identified. Based on cost implications, US is the most cost-effective strategy for THA patients.

Entities:  

Keywords:  Nasal decolonization; Periprosthetic joint infection; Screening; Staphylococcus aureus; Total hip arthroplasty

Mesh:

Year:  2021        PMID: 33522920      PMCID: PMC7849129          DOI: 10.1186/s12891-021-04008-y

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  34 in total

1.  Failure of decolonization in patients with infections due to mupirocin-resistant strains of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Christopher J Graber; Brian S Schwartz
Journal:  Infect Control Hosp Epidemiol       Date:  2008-03       Impact factor: 3.254

2.  A selected screening programme was less effective in the detection of methicillin-resistant Staphylococcus aureus colonisation in an orthopaedic unit.

Authors:  Jayshree Dave; Paul J Jenkins; Alison Hardie; Melvyn Smith; Paul Gaston; Alan P Gibb; Kate Templeton; Alastair H Simpson
Journal:  Int Orthop       Date:  2013-09-08       Impact factor: 3.075

3.  The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization.

Authors:  Kevin J Bozic; Michael D Ries
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

4.  Incidence and Risk Factors of Nasal Carriage of Staphylococcus aureus in HIV-Infected Individuals in Comparison to HIV-Uninfected Individuals: A Case-Control Study.

Authors:  Ruchi Kotpal; Krishna Prakash S; Preena Bhalla; Richa Dewan; Ravinder Kaur
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-10-20

5.  Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus.

Authors:  A R Caffrey; B J Quilliam; K L LaPlante
Journal:  J Hosp Infect       Date:  2010-09-16       Impact factor: 3.926

6.  Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis.

Authors:  Xan F Courville; Ivan M Tomek; Kathryn B Kirkland; Marian Birhle; Stephen R Kantor; Samuel R G Finlayson
Journal:  Infect Control Hosp Epidemiol       Date:  2012-02       Impact factor: 3.254

7.  Risk Factors for Staphylococcus aureus Nasal Colonization in Joint Arthroplasty Patients.

Authors:  Amanda L Walsh; Adam C Fields; James D Dieterich; Darwin D Chen; Michael J Bronson; Calin S Moucha
Journal:  J Arthroplasty       Date:  2017-12-29       Impact factor: 4.757

8.  Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement.

Authors:  Charlotte B Phillips; Jane A Barrett; Elena Losina; Nizar N Mahomed; Elizabeth A Lingard; Edward Guadagnoli; John A Baron; William H Harris; Robert Poss; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2003-01       Impact factor: 5.284

Review 9.  The Current State of Screening and Decolonization for the Prevention of Staphylococcus aureus Surgical Site Infection After Total Hip and Knee Arthroplasty.

Authors:  Mitchell C Weiser; Calin S Moucha
Journal:  J Bone Joint Surg Am       Date:  2015-09-02       Impact factor: 5.284

10.  Empiric treatment is less costly than Staphylococcus aureus screening and decolonization in total joint arthroplasty patients.

Authors:  Jacob Stirton; Joseph Scott Herron; Sumon Nandi
Journal:  Arthroplast Today       Date:  2017-12-30
View more
  1 in total

Review 1.  [Patient optimization before hip revision arthroplasty: : How to handle comorbidities].

Authors:  Max Jaenisch; Dieter Christian Wirtz
Journal:  Orthopadie (Heidelb)       Date:  2022-06-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.